Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.

ABSTRACT:

Background

This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAF^V600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.

Methods

The data were pooled from BRIM-2, BRIM-3, BRIM-7 and coBRIM. Association of depth of response with survival was estimated by Cox proportional hazards regression, adjusted for clinically relevant covariates. Depth of response was analysed in previously identified prognostic subgroups based on disease characteristics and gene signatures.

Results

Greater tumour reduction and longer time to maximal response were significantly associated with longer progression-free survival (PFS) and overall survival (OS) when evaluated as continuous variables

SUBMITTER: Lewis KD 

PROVIDER: S-EPMC6889491 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature